REUN - Earnings announcements

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and re

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion's fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023. The Company will hold a conference call and webcast to discuss its results at 8:30 a.m. ET the same day. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conferen